trending Market Intelligence /marketintelligence/en/news-insights/trending/ndrxlgjxd-uowffzocrwbq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA rejects Amphastar application for asthma inhaler

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Street Talk Episode 50 - Challenging The Legacy Core Bank Providers

Fed Poised To Relax Key Rules For Large Banks


US FDA rejects Amphastar application for asthma inhaler

The U.S. FDA withheld approval of Amphastar Pharmaceuticals Inc.'s over-the-counter asthma inhaler, Primatene Mist.

The regulator, in a complete response letter, asked the pharmaceutical company to make further changes to the inhaler's label and packaging followed by a study to evaluate patients' ability to use the product without professional guidance.

Amphastar plans to address these concerns by mid-2017.

The original Primatene Mist was discontinued because it contained chlorofluorocarbons, which are harmful to the ozone layer. The new version of the inhaler uses the same active ingredient as the old one but uses a different delivery system.